{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-142023","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.101730+00:00","generated_at":"2026-06-15T04:21:48.710007+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Spero Therapeutics reports Q1 2023 net loss of $13.3M; provides pipeline updates for SPR720, tebipenem HBr, and SPR206","bullets":["Net loss of $13.3M ($0.25 per share) in Q1 2023, compared to net loss of $32.8M ($1.01 per share) in Q1 2022.","Cash and cash equivalents of $96.3M as of March 31, 2023; company expects sufficient funding beyond 2024.","SPR720 Phase 2 trial in NTM-PD on track for top line data readout in first half of 2024.","Tebipenem HBr: SPA agreement update expected mid-2023; Phase 3 cUTI trial initiation expected in 2H 2023.","SPR206: IND submission for Phase 2 trial in hospital-acquired/ventilator-associated bacterial pneumonia expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-142023","json":"https://secwatch.observer/filing/0001193125-23-142023.json","markdown":"https://secwatch.observer/filing/0001193125-23-142023.md","text":"https://secwatch.observer/filing/0001193125-23-142023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/0001193125-23-142023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/d438048d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:21:48.710007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"429c187a7907473234dbe4a8cc94c94dc2adc83d","claim":"Spero Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Spero Therapeutics, Inc. (the “Company”) issued a press release announcing its results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1701108/000119312523142023/0001193125-23-142023-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}